Besides peptides, other monovalent vaccines were developed for HER2+ BC using other cancer-specific antigens such as MUC-1 vaccine in metastatic setting, WT1 vaccine for neodjuvant patients and gangliosides in adjuvant treatment, with some encouraging results. Here, WT1 is linked to breast cancer.